{"id":58755,"date":"2026-03-04T14:01:22","date_gmt":"2026-03-04T06:01:22","guid":{"rendered":"https:\/\/flcube.com\/?p=58755"},"modified":"2026-03-04T14:01:23","modified_gmt":"2026-03-04T06:01:23","slug":"aidea-pharma-raises-rmb-1-28b-111m-allocated-to-global-hiv-integrase-inhibitor-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58755","title":{"rendered":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development"},"content":{"rendered":"\n<p><strong>Jiangsu Aidea Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688488:SHA\">SHA:\u202f688488<\/a>)<\/strong> announced the completion of a <strong>financing round<\/strong> raising <strong>RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion)<\/strong>. The proceeds will fund <strong>global multi\u2011center clinical development<\/strong> of a <strong>novel HIV integrase inhibitor<\/strong> (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), <strong>consolidate control of Nanda Pharmaceutical<\/strong> (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and <strong>supplement working capital<\/strong> (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-allocation\">Financing Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Use of Funds<\/th><th>Amount<\/th><th>Percentage<\/th><th>Strategic Purpose<\/th><\/tr><\/thead><tbody><tr><td><strong>HIV Integrase Inhibitor Development<\/strong><\/td><td>RMB\u202f767\u202fM (USD\u202f111\u202fM)<\/td><td><strong>60%<\/strong><\/td><td>Global multi\u2011center trials (China + US)<\/td><\/tr><tr><td><strong>Nanda Pharmaceutical Acquisition<\/strong><\/td><td>RMB\u202f130\u202fM (USD\u202f18\u202fM)<\/td><td>10%<\/td><td>Consolidate control; deepen human protein expertise<\/td><\/tr><tr><td><strong>Working Capital<\/strong><\/td><td>RMB\u202f380\u202fM (USD\u202f55\u202fM)<\/td><td>30%<\/td><td>Core R&amp;D + commercial rollout<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-priorities\">Strategic Priorities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-hiv-integrase-inhibitor-global-development\">1. HIV Integrase Inhibitor \u2013 Global Development<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Novel HIV integrase inhibitor<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Global multi\u2011center trials<\/td><\/tr><tr><td><strong>Core Markets<\/strong><\/td><td>China + United States<\/td><\/tr><tr><td><strong>Investment<\/strong><\/td><td>RMB\u202f767\u202fmillion (~\u202f60% of total raise)<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>First\u2011in\u2011class or best\u2011in\u2011class HIV therapy addressing resistance and long\u2011acting needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-nanda-pharmaceutical-consolidation\">2. Nanda Pharmaceutical Consolidation<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Transaction<\/strong><\/td><td>Additional share acquisition<\/td><\/tr><tr><td><strong>Investment<\/strong><\/td><td>RMB\u202f130\u202fmillion<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Strengthen control; leverage human protein synergies for new drug R&amp;D<\/td><\/tr><tr><td><strong>Platform Value<\/strong><\/td><td>Human protein expertise supports biologics and complex formulation development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-working-capital-amp-commercialization\">3. Working Capital &amp; Commercialization<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Allocation<\/strong><\/td><td>RMB\u202f380\u202fmillion<\/td><\/tr><tr><td><strong>Purpose<\/strong><\/td><td>Core research continuity + commercial infrastructure build\u2011out<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV Innovation Focus:<\/strong> The <strong>60% allocation to HIV integrase inhibitor<\/strong> signals <strong>Aidea&#8217;s strategic bet<\/strong> on <strong>next\u2011generation antiretroviral therapy<\/strong>\u2014potentially addressing <strong>resistance mutations<\/strong>, <strong>long\u2011acting formulations<\/strong>, or <strong>improved safety profiles<\/strong> vs. existing integrase inhibitors (dolutegravir, bictegravir).<\/li>\n\n\n\n<li><strong>Global Clinical Ambition:<\/strong> <strong>China + US multi\u2011center trials<\/strong> position Aidea for <strong>simultaneous regulatory submissions<\/strong> and <strong>global partnership attractiveness<\/strong>\u2014rare for <strong>domestic Chinese infectious disease developers<\/strong>.<\/li>\n\n\n\n<li><strong>Nanda Synergies:<\/strong> <strong>Human protein platform consolidation<\/strong> enables <strong>biologics manufacturing capabilities<\/strong> and <strong>complex formulation expertise<\/strong>, supporting <strong>HIV drug delivery innovation<\/strong> (e.g., long\u2011acting injectables).<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> The <strong>three\u2011pronged allocation<\/strong> balances <strong>high\u2011risk R&amp;D<\/strong> (HIV), <strong>strategic M&amp;A<\/strong> (Nanda), and <strong>operational runway<\/strong> (working capital)\u2014demonstrating <strong>disciplined capital deployment<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>HIV Market Size<\/strong><\/td><td>~\u202f$30\u202fbillion globally; integrase inhibitors dominate first\u2011line; resistance and long\u2011acting needs drive next\u2011gen innovation<\/td><\/tr><tr><td><strong>China HIV Burden<\/strong><\/td><td>~\u202f1.2\u202fmillion people living with HIV; growing government investment in domestic antiretroviral development<\/td><\/tr><tr><td><strong>Integrase Inhibitor Competition<\/strong><\/td><td>GSK&#8217;s dolutegravir, Gilead&#8217;s bictegravir established; Aidea&#8217;s novel mechanism must demonstrate differentiation (resistance profile, dosing convenience, safety)<\/td><\/tr><tr><td><strong>Aidea Pipeline Depth<\/strong><\/td><td>Financing supports <strong>HIV lead asset<\/strong> while Nanda integration enables <strong>platform expansion<\/strong> into other infectious diseases or protein therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HIV integrase inhibitor Phase I\/II initiation, Nanda integration synergies, and global regulatory pathway execution. Actual results may differ due to risks including competitive GSK\/Gilead advancement, HIV resistance evolution, and manufacturing scale\u2011up challenges for novel formulations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58758,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[619,20,988],"class_list":["post-58755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aidea-pharmaceutical","tag-finance","tag-sha-688488"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58755\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58755\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T06:01:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T06:01:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development\",\"datePublished\":\"2026-03-04T06:01:22+00:00\",\"dateModified\":\"2026-03-04T06:01:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0406.webp\",\"keywords\":[\"Aidea Pharmaceutical\",\"Finance\",\"SHA: 688488\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58755#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58755\",\"name\":\"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0406.webp\",\"datePublished\":\"2026-03-04T06:01:22+00:00\",\"dateModified\":\"2026-03-04T06:01:23+00:00\",\"description\":\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \\\/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \\\/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \\\/ USD\u202f55\u202fmillion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58755\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0406.webp\",\"width\":1080,\"height\":608,\"caption\":\"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58755#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58755","og_locale":"en_US","og_type":"article","og_title":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development","og_description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).","og_url":"https:\/\/flcube.com\/?p=58755","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T06:01:22+00:00","article_modified_time":"2026-03-04T06:01:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58755#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58755"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development","datePublished":"2026-03-04T06:01:22+00:00","dateModified":"2026-03-04T06:01:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58755"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58755#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","keywords":["Aidea Pharmaceutical","Finance","SHA: 688488"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58755#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58755","url":"https:\/\/flcube.com\/?p=58755","name":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58755#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58755#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","datePublished":"2026-03-04T06:01:22+00:00","dateModified":"2026-03-04T06:01:23+00:00","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA:\u202f688488) announced the completion of a financing round raising RMB\u202f1.277\u202fbillion (~\u202fUSD\u202f184\u202fmillion). The proceeds will fund global multi\u2011center clinical development of a novel HIV integrase inhibitor (RMB\u202f767\u202fmillion \/ USD\u202f111\u202fmillion), consolidate control of Nanda Pharmaceutical (RMB\u202f130\u202fmillion \/ USD\u202f18\u202fmillion), and supplement working capital (RMB\u202f380\u202fmillion \/ USD\u202f55\u202fmillion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58755#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58755"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58755#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","width":1080,"height":608,"caption":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58755#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aidea Pharma Raises RMB 1.28B \u2013 $111M Allocated to Global HIV Integrase Inhibitor Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58755"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58755\/revisions"}],"predecessor-version":[{"id":58759,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58755\/revisions\/58759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58758"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}